Partial
Mostly Aligned
Patient Risk:
Medium
Summary
Some statements are supported by the label (HMG-CoA reductase inhibition, mechanism affecting LDL, reporting muscle pain, and monitoring/closer monitoring for skeletal muscle and renal impairment risk in rhabdomyolysis). However, multiple claims about vitamin D specifically, kidney problems, and exact incidence percentages in a study are not supported by the provided prescribing information.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is an HMG-CoA reductase inhibitor.
11 DESCRIPTION: “Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.”; 12.1 Mechanism of Action: “selective, competitive inhibitor of HMG-CoA reductase.”
Lipitor reduces the production of low-density lipoprotein (LDL) cholesterol in the liver.
12.1 Mechanism of Action: “In animal models… lowers plasma cholesterol… by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver…” and “…LIPITOR also reduces LDL production…”
Patients should report muscle pain or weakness to their healthcare provider.
5.1 Skeletal Muscle: “Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness…”; 17.1 Muscle Pain: “told to report promptly any unexplained muscle pain, tenderness, or weakness.”
Unsupported Statements
Lipitor can increase the risk of muscle damage when taken with certain medications, including vitamin D supplements.
Label sections provided discuss increased myopathy/rhabdomyolysis risk with specific interacting agents (e.g., cyclosporine, strong CYP3A4 inhibitors, fibric acid derivatives, erythromycin/clarithromycin, niacin, azole antifungals), but vitamin D supplements are not mentioned.
Lipitor can increase the risk of kidney problems when taken with certain medications, including vitamin D supplements.
Provided label text links renal failure secondary to rhabdomyolysis as a risk context, but does not mention vitamin D supplements or any vitamin D-related kidney-problem interaction.
Combining Lipitor with vitamin D supplements may increase the risk of muscle damage in some individuals.
No vitamin D interaction is supported in the provided prescribing information.
In a study, 12% of patients who took Lipitor and vitamin D supplements for at least 6 months experienced muscle damage.
No study data with vitamin D coadministration and these incidence percentages are provided in the supplied label text.
In a study, 8% of patients who took Lipitor and vitamin D supplements for at least 6 months experienced kidney problems.
No study data with vitamin D coadministration and these incidence percentages are provided in the supplied label text.
Combining Lipitor and vitamin D supplements may increase the risk of kidney problems in some individuals.
No vitamin D interaction is supported in the provided prescribing information.
Patients should monitor muscle and kidney function regularly when taking Lipitor and vitamin D.
The label advises closer monitoring for skeletal muscle effects in patients with renal impairment risk and suggests periodic CPK determinations may be considered in certain interaction scenarios, but it does not support kidney-function monitoring specifically in relation to vitamin D.
Patients should not take high doses of vitamin D supplements without consulting their healthcare provider.
No guidance regarding vitamin D dosing is present in the provided label text.
Patients should consult their healthcare provider before combining Lipitor and vitamin D.
Label advises discussing all prescription/OTC medications with a healthcare professional, but it does not specifically mention vitamin D; therefore this vitamin D-specific counseling is not supported by the supplied label.
By lowering LDL cholesterol, Lipitor helps to reduce the risk of heart disease and stroke.
The provided label excerpt describes that elevated total-C/LDL-C promote atherosclerosis and are risk factors for cardiovascular disease, but it does not explicitly state that Lipitor reduces risk of heart disease and stroke in the provided sections.
Contradictions
Important Omissions
Label-based monitoring specifics for skeletal muscle/CPK and guidance for liver function testing (prior to and at 12 weeks after initiation or dose increases; then periodically) were not mentioned in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Vitamin D-specific interaction claims, kidney-problem risk claims, and exact incidence percentages are unsupported by the provided label text. Unsupported counseling and monitoring directives tied to vitamin D could mislead users.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Vitamin D–specific interaction assertions (muscle damage and kidney problems), exact incidence percentages, and vitamin D dosing counseling are not supported by the provided prescribing information.
Suggested Improvement
Remove or replace vitamin D-specific claims and the cited study percentages with statements that align to label-supported interacting agents (e.g., cyclosporine/strong CYP3A4 inhibitors, fibric acid derivatives, niacin, azoles) and label-supported risk/counseling (report unexplained muscle pain; consider closer monitoring/CPK in appropriate interaction scenarios; renal impairment is a risk factor for rhabdomyolysis-related renal failure).